Einfluss des Alters auf das karzinomspezifische Überleben nach radikaler Zystektomie

M, May; Fritsche, Hans‐Martin; Gilfrich, Christian; Brookman‐May, Sabine; Burger, Maximilian; Otto, Wolfgang; Bolenz, Christian; Trojan, Lutz; Herrmann, Edwin; Michel, Maurice Stephan; Wülfing, Christian; Tiemann, A.; Müller, Stefan; Ellinger, Jörg; Büchner, Alexander; Stief, Christian G.; Tilki, Derya; Höfner, Thomas; Hohenfellner, Markus; Haferkamp, Axel; Roigas, Jan; Müller, Oliver; Bretschneider-Ehrenberg, P.; Zacharias, Mario; Gunia, Sven; Bastian, Patrick J.

doi:10.1007/s00120-011-2507-9

Cited by 19 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Older patients have been found to have higher stage at diagnosis, higher rate of upstaging on final pathology and a longer delay to definitive therapy [ 17 18 19 20 ]. When selecting patients to undergo RadC, the institution and urologist (training and experience) are important in the outcome of the procedure [ 21 ].…”

Section: Elderly Population Undergoing Bladder Cancer Treatments (Radmentioning

confidence: 99%

“…Age has been found to be a predictive factor for 90-date mortality following RadC in a multinational study from 18 European centres [ 38 ]. Other studies have also reported 90-day mortality rates increase with age; 5.5% in patients ≥65 years [ 39 ], 6.2%–7.5% in those ≥75 years [ 18 40 ], and 10%–11% in those ≥80 years [ 41 42 ].…”

Section: Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of bladder cancer in the elderly

Erlich

Zlotta

2016

Investig Clin Urol

View full text Add to dashboard Cite

As the population ages and life expectancy increases in the human population, more individuals will be diagnosed with bladder cancer (BC). The definition of who is elderly is likely to change in the future from the commonly used cut-off of ≥75 years of age. Physiological rather than chronological age is key. BC care in the elderly is likely to become a very common problem in daily practice. Concerns have been raised that senior BC patients are not given treatments that could cure their disease. Clinicians lack quantitative and reliable estimates of competing mortality risks when considering treatments for BC. Majority of patients diagnosed with BC are elderly, making treatment decisions complex with their increasing number of comorbidities. A multidisciplinary approach to these patients may be a way to incorporate discussion from various disciplines regarding treatment options available. Here we review various treatment options for elderly patients with muscle invasive BC and nonmuscle invasive BC. We include differences in treatments from robotic versus open radical cystectomy, various urinary diversion techniques, chemotherapy, radiation therapy and combination treatments. In clinical practice, treatment decisions for elderly patients should be done on a case-by-case basis, tailored to each patient with their specific histories and comorbidities considered. Some healthy elderly patients may be better candidates for extensive curative treatments than their younger counterparts. This implies that these important, life-altering decisions cannot be solely based on age as many other factors can affect patient survival outcomes.

show abstract